Danish Oil and Gas Stock News

Alm. Brand Q1 2026 earnings snapshot Alm. Brand (CPSE:ALMB) has followed up its recent Q4 2025 result with total revenue of DKK 3.98b and basic EPS of DKK 0.23, supported over the last 12 months by a net profit margin of 8.2% versus 5.7% in the prior period. Over recent quarters the company has seen revenue range between DKK 3.26b and DKK 3.98b, while quarterly basic EPS has moved between DKK 0.11 and DKK 0.23, alongside trailing EPS growth of 49.3% year over year. Taken together, these...

DSV (CPSE:DSV) opened 2026 with Q1 results anchored by prior quarter revenue of about DKK71.7b and basic EPS of DKK4.72, set against trailing 12 month revenue of roughly DKK247.3b and EPS of DKK35.57. Over recent quarters, revenue has moved from about DKK43.5b in Q4 2024 to the DKK71.7b level in Q4 2025, while quarterly EPS shifted from DKK9.46 to DKK4.72, leaving investors focused on how much of the top line is converting into sustainable margins. See our full analysis for DSV. With the...

Ringkjøbing Landbobank (CPSE:RILBA) has put up another solid scorecard, with trailing twelve month revenue of DKK4.2b and basic EPS of DKK92.86 framing the latest Q1 2026 update, while reported net profit margin sits at 55.7% versus 55.6% a year earlier. Over recent quarters, the bank has seen quarterly revenue move in a tight band between DKK1,003.19m and DKK1,073.47m and basic EPS range from DKK20.68 to DKK23.87, giving investors a clear earnings profile supported by firm margins rather...

Novo Nordisk has entered a partnership with OpenAI to apply advanced AI tools across drug discovery and development. Health Canada has approved a generic version of semaglutide, the active ingredient in Ozempic, for diabetes treatment. This is the first approval of a generic GLP-1 semaglutide in a G7 country, introducing a new competitor to Ozempic in Canada. Novo Nordisk, traded as CPSE:NOVO B, sits at the center of two major shifts that directly touch its core GLP-1 franchise and long...

Embla Medical hf (CPSE:EMBLA) has opened 2026 with Q1 revenue of US$232.4 million and basic EPS of US$0.034, setting the tone for how its earnings story is evolving against a current share price of DKK26.9. Over the past year, the company has seen trailing twelve month revenue move from US$854.9 million to US$958.3 million while basic EPS on the same basis went from US$0.160 to US$0.202. This gives investors a clearer view of how the top and bottom lines are tracking into this latest quarter...

Wondering if Rockwool at a last close of DKK 185.8 is starting to look attractive, or if the price still does not quite line up with the underlying business. The stock has been choppy, with a 4.7% decline over the last 7 days, a 6.3% gain over 30 days, and longer-term returns of a 17.2% decline year to date and a 35.4% decline over 1 year, while the 3-year return sits at 19.9% and the 5-year return at a 24.0% decline. Recent coverage around Rockwool has focused on how the share price path...

If you are wondering whether AL Sydbank at around kr.544.50 is still offering value or if most of the opportunity is already priced in, you are in the right place. The share price has moved around recently, with a 3% decline over the last 7 days, an 8.4% gain over the last 30 days, a 4.6% decline year to date, and a 37.2% return over the past year, capped by very large gains over 3 and 5 years. These swings have been accompanied by ongoing interest in the Danish banking sector and investor...

If you are wondering whether DSV’s current share price reflects its underlying value, this article walks through the key signals that matter for valuation focused investors. Over the past year, DSV has returned 29.8%, with moves like an 11.2% return over the last 30 days and a 2.3% decline over the last week, which may hint at changing sentiment and risk appetite. Recent evergreen coverage interest has kept attention on how DSV is priced versus fundamentals, and has brought valuation back...

ISS has recently expanded its partnership with the Fulham Road Collaborative in the UK, securing a five-year, approximately DKK 100 million per year contract to provide integrated facility services across three major hospital sites, while also deepening its global workplace technology offering through a new partnership with Sign In Solutions. Together, the enlarged UK healthcare contract and the integration of Sign In Solutions into ISS’s Convenie platform highlight the group’s push to...

Wondering if Novo Nordisk at DKK 265.8 still offers value, or if the best opportunity is already behind you? This article walks through what the current price actually reflects. The stock has moved sharply in the short term, with a 7.6% return over 7 days and 16.3% over 30 days, set against a year to date return of 19.5% decline and a 34.5% decline over the last year. These swings sit in the context of ongoing attention on Novo Nordisk's role in global pharmaceuticals, including regular...

Why Københavns Lufthavne Is On Investors’ Radar Københavns Lufthavne (CPSE:KBHL) has come into focus after a recent spell of weaker share performance, with negative returns over the past month, past 3 months and year prompting closer attention to its fundamentals. See our latest analysis for Københavns Lufthavne. With the share price at DKK5,880, Københavns Lufthavne has recorded a 6.67% decline over the past month and a 14.04% year-to-date share price retreat, alongside a 10.64% one-year...

For investors wondering whether ALK-Abelló’s current share price reflects its real worth or whether the market is getting ahead of itself, this breakdown focuses squarely on what you are paying versus what you are getting. With the stock at DKK 229.2 and returns of 2.7% over 7 days, 13.5% over 30 days, 1.1% year to date, 59.1% over 1 year, 167.0% over 3 years and 73.6% over 5 years, recent performance provides important context for any valuation view. Recent attention around ALK-Abelló has...

Vestas Wind Systems (CPSE:VWS) has attracted fresh attention after securing a 70 MW order from Tessa Green Energy for Bulgaria’s Strazhitsa wind project, paired with a long-term Active Output Management 5000 service agreement. See our latest analysis for Vestas Wind Systems. The new Bulgaria contract lands as Vestas’ share price trades at DKK192.0, with a 1 month share price return of 9.18% and a 1 year total shareholder return of 118.53%. This points to recent momentum following a mixed 3...

Why Carlsberg’s expanded PepsiCo partnership matters for shareholders Carlsberg (CPSE:CARL B) has agreed to expand its long running collaboration with PepsiCo, taking over bottling in Denmark, Finland and the Baltic states from 2029 as existing Coca-Cola arrangements conclude. For you as an investor, this shift means Carlsberg is set to handle production, sales and distribution of PepsiCo drinks across all Nordic markets, plus Latvia, Estonia and Lithuania. That extends an arrangement that...

Royal Unibrew A/S ( CPH:RBREW ) stock is about to trade ex-dividend in 2 days. The ex-dividend date generally occurs...

Earlier this month, Novo Nordisk reported positive Phase 3a PIONEER TEENS results showing its oral semaglutide cut HbA1c significantly versus placebo in 10–17-year-olds with type 2 diabetes, and said it plans to seek US and EU label expansions in the second half of 2026. By opening the door for the first oral GLP-1 therapy in youth-onset type 2 diabetes, Novo Nordisk is targeting a large, under-treated global patient group where current options like metformin and insulin have important...

H. Lundbeck (CPSE:HLUN B) shares are in focus after the company reported new 6 month real world INFUSE study results for migraine drug eptinezumab at the American Academy of Neurology 2026 meeting. See our latest analysis for H. Lundbeck. The eptinezumab data arrives at a time when H. Lundbeck’s short term momentum is positive, with a 14.59% 1 month share price return and a 54.44% 1 year total shareholder return. However, the 90 day share price return of 2.16% decline suggests some earlier...

Coloplast recently revised its FY 2025/26 guidance, trimming expected organic growth to 5–6% and EBIT growth to around 5%, while recording a DKK 3.00 billion goodwill impairment on Kerecis following sales disruption from a Medicare reimbursement change and softer skin substitutes demand. This combination of lower growth expectations and a large impairment charge highlights how reimbursement shifts in a single niche can materially affect Coloplast’s broader outlook and capital allocation...

Readers hoping to buy SP Group A/S ( CPH:SPG ) for its dividend will need to make their move shortly, as the stock is...

Novo Nordisk (CPSE:NOVO B) has just presented new clinical data to investors, with oral semaglutide in youth type 2 diabetes and etavopivat in sickle cell disease both meeting key late-stage trial goals. See our latest analysis for Novo Nordisk. The latest trial wins arrive after a volatile stretch, with a 1 day share price return of 5.37% and a 30 day share price return of 10.24% helping to stabilise momentum following a 90 day share price return decline of 35.23% and a 1 year total...

Why Danske Bank is on investors’ radar today Danske Bank (CPSE:DANSKE) is drawing attention as investors weigh its current share price of DKK 320.5 against recent returns and valuation metrics, including value score and estimated discount to intrinsic value. See our latest analysis for Danske Bank. Recent trading has been a bit softer, with a 7 day share price return of 3.98% and a modest 30 day share price return of 0.79%. Investors are reassessing earlier gains against Danske Bank's current...

Coloplast (CPSE:COLO B) has cut its 2025/26 guidance, trimming expected organic growth to 5–6% and EBIT growth to around 5%, while recording a DKK 3.0b goodwill impairment linked to Kerecis. See our latest analysis for Coloplast. The guidance cut and Kerecis impairment appear to be weighing on sentiment, with a 7 day share price return of 7.89% and a 90 day share price return of 23.75% contributing to a 1 year total shareholder return of 40.76%, which may suggest fading momentum despite the...

Zealand Pharma (CPSE:ZEAL) has been removed from multiple major S&P indices, affecting its presence in index-tracking portfolios. The index changes have already taken effect, altering how the company features in benchmark-based investment products. Separately, Zealand Pharma has appointed Eric Rojas as Vice President and Head of Investor Relations. Rojas brings experience in investor communications, with a mandate to lead the company’s engagement with the capital markets. Zealand Pharma...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...